New clinical studies have shown substantial optimism regarding the drug gantenerumab, a biological agent designed to clear amyloid-beta plaques from the brain. Despite past studies at amyloid-targeting therapies have met difficulties, gantenerumab's distinct action and favorable early data imply it may offer a greater chance of modifying the progre